As 20–25% of the aggressive ATC cases display BRAFV600E mutation, we sought to verify, likewise reported in BRAF-driven PTCs, the presence of a BRAF-mediated glycolytic phenotype in this tumor and if B-raf inhibitors are able to restrain it. The gene discussed is BRAF; the disease is neoplasm.